Correction to: ROS dependent antitumour activity of photo-activated iron(III) complexes of amino acids

Photochemotherapeutic Properties of Cu(II) Complexes of L‐Lysine and L‐Arginine Appended to Anthracene

“…[5][6][7][8][9] Use of light to activate a compound, which is otherwise non-toxic in dark, is an excellent strategy to treat cancer without affecting the normal cells. [1,10] Various tetrapyrrolic macrocycles such as Photofrin, Verteporfin, Temoporfin etc. have been successfully tested and approved for treating various cancers.…”

“…Since the most widely used metal‐based anticancer drug cisplatin and its next‐generation compounds have systemic toxicity and tumors develop resistance against these drugs, lot of investigations have been carried out over the past few decades in search of alternate metal‐based antitumor compounds that can overcome the problems associated with platinum drugs [5–9] . Use of light to activate a compound, which is otherwise non‐toxic in dark, is an excellent strategy to treat cancer without affecting the normal cells [1,10] . Various tetrapyrrolic macrocycles such as Photofrin, Verteporfin, Temoporfin etc.…”

“…This resulted in a significant number of reports on 3d metal complexes having suitably designed ligands for photochemotherapeutic applications in recent time. [10,[22][23][24][25] Amino acids are bio-essential compounds that can chelate to transition metals to form stable complexes. Amino acid conjugates are popularly used for biocompatible ligand design for various biomedical applications.…”

“…They can generate cytotoxic reactive oxygen species in low energy visible light and thus potentially act as photochemotherapeutic agents with lower systemic toxicity in dark. This resulted in a significant number of reports on 3d metal complexes having suitably designed ligands for photochemotherapeutic applications in recent time [10,22–25] . Amino acids are bio‐essential compounds that can chelate to transition metals to form stable complexes.…”

Iron(III) Complex-Functionalized Gold Nanocomposite as a Strategic Tool for Targeted Photochemotherapy in Red Light

“…The complexation of iron­(III) with the π-donor ligands in an octahedral geometry typically results in a reduced energy gap between t 2g and e g * molecular orbitals − that lead to low-energy metal-centered or ligand-to-metal charge-transfer (LMCT) transition with the typical wavelength of absorption in the range of 450–600 nm. − When such complexes are activated with light at the LMCT band, there is typical homolytic fission of the metal–ligand bond, which consequently leads to the oxidation of the ligand (carboxylate-O or phenolate-O) and reduction of the iron­(III) center to iron­(II). − Such a light-induced intramolecular redox reaction is typically responsible for the generation of extremely cytotoxic ROS, such as superoxide anions (O 2 •– ) and hydroxyl radicals. − Therefore, the ability of the phenolate or carboxylate-based complexes of iron­(III) to yield ROS with low-energy or longer-wavelength light activation has shown potential as a promising strategic tool for photochemotherapeutic utility. Recently, our group, along with Chakravarty et al, has reported visible-light-induced hydroxyl radical-mediated photocytotoxicity with iron­(III)-phenolate/carboxylate-based complexes in different cancer cells. − However, the complexes did not satisfy the criteria for being ideal photochemotherapeutic agents as the majority of the iron­(III) complexes lacked target-specificity and showed photocytotoxicity only in the visible light (<600 nm).…”